Som en ekte linjalgnukker vil jeg nå ikke ha den på 40, men på 37,7
2 Likes
Lurer på om vi skal ned og lukte på “lower lows” her, eller hva nå dere som kan lese strekene kaller det.
GPCR var nede på 35,8 her i vår, og så var den en runde til og svima rundt på 37-ish, før den tok turen opp mot 55 i sommer igjen, før ny nedtur nå.
1 Like
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes
1 Like
Hull er det vel ikke akkurat, meeeeeeeen man kan jo bare merke zeg at danzkene i Sjællands Apotek stadig vekk får interesse, herfra og derfra. Kurzen er ned, og skal trolig mer ned på petrelintid i t2d (guida topline i q3 i år), fordi markedet nok har litt for luftige forhåpninger til hva en amylinagonist kan gjøre for t2d-populasjonen.
Men kan være det blir en fin købsandledning? Som de sier i DK: køb når dær er blod på sykelstien
1 Like
«Of up to 9,8%» er noe ganske annet enn å si hva snittet var
Kort duration, nesten bare menn i studien (mister mindre vekt enn kvinnfolk), lav utgangs-BMI (pleier å være rundt 37 i mange studier)
Jeg vil hevde at et utfall mellom 7,5% placebojustert til 9,2 eller 9,3 i gjennomsnittlig vekttap er ganske fine tall for en sånn gruppe. Står ikke så mye om toleransen, den som blir interessant her
11 dager half-life, også, ser ikke ut til at det er noen vits å dosere hyppigere enn annenhver uke / måned.
Ingen reaksjon på Gubra, btw. Men man kan jo fint hevde at Gubra kanskje har vært alt for høyt priset og begynner å nærme seg en mer riktig prising?
Edit: Når jeg skriver: “Menn mister mindre vekt enn kvinnfolk” så baserer jeg det på det vi vet fra inkretiner (som glp-1s), det kan være at menn og kvinner mister vekt mer jevnt på amylinanaloger, det vil kun tiden vise.
Var ikke reta, nei, men kjempedose med sema 
Au
experienced uncontrollable vomiting, resulting in a torn oesophagus
amount of semaglutide detected was approximately 8 times higher than the level found in semaglutide products assessed by the TGA
Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
Provided by Business Wire Sep 22, 2026, 7:05:00 AM
Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
● At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic control
● In patients with poor baseline glycemic control (HbA1c >8.5%), enicepatide 24 mg led to an HbA1c reduction of 4.13% at 48 weeks
● By week 48, 90% of patients in the 24 mg enicepatide arm met the T2D glycemic target of ≤6.5% HbA1c, while 62% achieved normoglycemia (HbA1c < 5.7%)
● At the highest 24 mg dose, enicepatide achieved a mean weight loss of 15.5% at 48 weeks, without a weight loss plateau
● Enicepatide demonstrated a safety and tolerability profile consistent with the incretin class, with low discontinuation rates and no new safety signals identified
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today announced positive topline results from CT-388-104, a Phase II clinical trial evaluating enicepatide (CT-388), an investigational, once-weekly dual GLP-1/GIP receptor agonist, in adults living with type 2 diabetes (T2D) and overweight or obesity. In the study, enicepatide met both primary endpoints, delivering dose-dependent and clinically meaningful reductions in blood glucose and body weight at 48 weeks. Patients receiving the highest titrated dose (24 mg) achieved an HbA1c reduction of 2.65% (from a baseline HbA1c of 8.1%). Furthermore, 90% of patients in the 24 mg cohort reached an HbA1c level of ≤6.5% (diagnostic threshold for T2D) and 62% achieved normoglycemia (HbA1c < 5.7%), restoring blood glucose levels to a non-diabetic range. The mean weight loss at 48 weeks in the 24 mg enicepatide arm was 15.5% without a demonstrable plateau.
The safety and tolerability profile of enicepatide was consistent with other established incretin-based therapies, with the most common adverse events being predominantly mild-to-moderate gastrointestinal effects. In addition, the treatment discontinuation rate due to adverse events was low (2.0% in enicepatide arms; 0.0% in placebo arm).
The totality of data positions enicepatide, a unique dually biased GLP-1/GIP receptor agonist, as a differentiated molecule designed for potentially greater efficacy with a favorable safety profile.
“We are highly encouraged by the efficacy demonstrated by enicepatide in this Phase II study, including the meaningful proportion of patients reaching normalized glucose levels within less than a year of treatment,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “Combined with sustained weight loss, enicepatide offers a potential best-in-disease profile capable of reducing and preventing complications as well as enhancing metabolic health for people living with type 2 diabetes.”
Genentech is advancing a broad late-stage development program for enicepatide, including two ongoing Phase III studies in chronic weight management (ENITH-1 and ENITH-2) and plans to initiate a Phase III glycemic-control program and cardiovascular outcomes trials in the first half of 2027.
“These results reinforce our confidence in enicepatide and our ambition to rapidly advance its development for people living with obesity, diabetes, and cardiovascular disease,” said Teresa Graham, chief executive officer, Pharma. “As we expand into late-stage clinical studies and explore novel combinations, we are leveraging our integrated diagnostic and therapeutic expertise to build a competitive cardiometabolic portfolio — aiming to protect people from early metabolic dysfunction to advanced organ damage, ultimately reducing the global disease burden.”
About the enicepatide 104 Phase II study [NCT06628362]
The CT-388-104 study is a randomized, double-blind, placebo-controlled, parallel-group, multi-center Phase II trial evaluating the efficacy, safety, and tolerability of once-weekly enicepatide administered subcutaneously for 48 weeks in 447 adults living with T2DM and overweight or obesity. The dual primary outcomes are changes from baseline in HbA1c and body weight at week 48.
About enicepatide
Enicepatide is an investigational once-weekly subcutaneous injectable, dually biased GLP-1/GIP receptor agonist in development for the treatment of obesity, type 2 diabetes, and additional cardiovascular indications. It aims to reduce appetite and regulate blood sugar by selectively targeting and activating both receptors which integrate nutrient-derived signals to control energy homeostasis. Enicepatide was designed to have potent activation of both GLP-1 and GIP receptors, but with minimal to no ß-arrestin recruitment on either receptor. This biased signalling significantly minimizes receptor internalization and consequent desensitization, which is expected to lead to prolonged pharmacological activity.
1 Like
Foundayo lansert i 4-5 internasjonale markeder og mange flere forventes neste 6 mnd
1 av 3 nye pillepasienter på Foundayo
700000 nye seniorer på Medicare Bridge (hvor Lilly tar 7 av 10, hovedsaklig Zepbound)
Foundayo diabetes type 2 godkjenning forventet innen årsslutt
Fremhever nye data som kommer på EASD (Foundayo, Retatrutid og ikke minst Eloralintide)
1 Like
Det er selvfølgelig ikke akkurat overveldende at kun 1 av 3 nye pillepasienter er på orforglipron aka Foundayo, meeeen: Vi kan jo også observere at medikamentet har overlevd å bli lansert samt brukt av en relativt stor populasjon.
Frykten for at levertox skulle kunne bli en hindring for medikamentet IRL tror jeg man nå kan se bort fra.
Jeg tror dermed vi kan konkludere med at ikke-peptide oral small molecules er en klasse fedmedrugs som har kommet for å bli
Skikkelig fine tall på enicepatide, tilsynelatende bedre enn tirze, både på Hb1Ac-reduksjon og vekttap for t2d pasientene… sammenligner med surpass 2,3,4. Og toleransen også… relativt spent på hvordan dataene sammen med petrelintid i vanlig fedme blir… vil den kunne matche tirze/elora-komboen på efficacy og/eller toleranse?
1 Like
Konklusjon: Generisk semaglutide er ikke i nærheten av like bra kvalitet som Novo sin sema?
Tror ikke det er så mye kvalitet, men mengde, det går på her.
Stort sett det jeg har sett av tester på godkjent generisk semaglutide så skal det være relativt on par (selvom det nok ikke er godkjent produkt det er snakk om i dette her)
1 Like
" 22% Placebo-Adjusted Weight Loss Reported at Week 33 Following Weekly Dosing of VK2735 at 17.5 mg; No Plateau Observed
Results Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight Loss; Increasing Options for Adherence to Treatment
Up to 97% of Weight Loss Maintained Following Transition to Every Other Week Dosing for Three Months
Up to 90% of Weight Loss Maintained Following Transition to Monthly Dosing for Three Months
Excellent Tolerability Observed During Maintenance Dosing with GI Adverse Event Rates Similar to Placebo
Conference Call Scheduled for 8:00 a.m. ET Today
duplo-varianten: 22% vekttap på 33 uker ikke platå, lav n, men åkkesom
Fine data fra vikingene i San Diego dette.
Betyr at den helt fint matcher tirze og trolig også enicepatide på vekttapsdelen.
Og det lange half-lifet til vk2735 kommer til sin rett her, går altså ganske fint å legge seg på dosering hver 14 dag eller hver måned og beholde mesteparten av vekttapet
1 Like
Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity
2026-09-22 17:00:00
Press release – No. 17 / 2026
Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity
- The Phase 3 initiation marks a defining step toward establishing petrelintide as a future first-choice therapy for millions of people living with overweight or obesity
- The global Phase 3a ZUPREME program consists of three trials, designed to support marketing applications for petrelintide monotherapy in chronic weight management
- The Phase 3a program builds on positive Phase 2 results, which demonstrated double-digit weight loss with a tolerability profile largely comparable to placebo, supporting petrelintide’s potential to redefine the weight management experience for people living with obesity or overweight
Copenhagen, Denmark, September 22, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces the initiation of the global registrational Phase 3 ZUPREME program, evaluating the efficacy and safety of once-weekly petrelintide versus placebo in people with overweight or obesity.
The Phase 3a program for petrelintide monotherapy, which is being conducted with Zealand Pharma’s partner Roche, consists of three trials: ZUPREME-3, ZUPREME-4, and ZUPREME-5, evaluating the efficacy and safety of once-weekly petrelintide versus placebo in people with obesity or overweight without type 2 diabetes, people with obesity or overweight with type 2 diabetes, and people with obesity or overweight and established cardiovascular disease, respectively. The three trials are expected to enroll approximately 7,000 participants in total.
“ The Phase 3a program is designed to confirm the first-choice potential of petrelintide – supported by the data we have seen throughout the clinical trials with petrelintide: clinically meaningful double-digit weight reduction and a tolerability profile that supports the long-term adherence that chronic weight management requires ,” said David Kendall, MD, Chief Medical Officer at Zealand Pharma. ” The program is designed to generate the robust, longer-term evidence needed to support regulatory filings and bring petrelintide to the millions of people demanding a better weight management experience .”
About the Phase 3a ZUPREME program
ZUPREME-3 is a randomized, double-blind, placebo-controlled, Phase 3 trial, evaluating the efficacy and safety of once-weekly petrelintide compared with placebo in participants living with overweight (BMI ≥ 27 < 30 kg/m2) or obesity (BMI ≥ 30 kg/m2) with at least one weight-related comorbidity without type 2 diabetes (T2D). The trial will enroll a total of approximately 3,900 participants.ZUPREME-4 is a randomized, double-blind, placebo-controlled, Phase 3 trial, evaluating the efficacy and safety of once-weekly petrelintide compared with placebo in participants living with overweight or obesity and T2D. The trial will enroll a total of approximately 600 participants.
The ZUPREME-3 and ZUPREME-4 trials include a screening period, a dose escalation period of 12 weeks followed by a maintenance period until week 64, and a safety follow-up period after treatment is completed until week 77. All participants who complete the week 64 visit will be eligible to continue in an optional open-label extension (OLE) study. Participants in the OLE study will be offered treatment with petrelintide regardless of which treatment arm they were allocated in the main study.
ZUPREME-5 is a randomized, double-blind, placebo-controlled, Phase 3 trial, evaluating the efficacy and safety of once-weekly petrelintide in participants living with overweight or obesity and established cardiovascular disease (CVD) with or without T2D. ZUPREME-5 includes a screening period, a dose escalation period of 12 weeks followed by a maintenance period, with the primary efficacy assessment occurring at week 64. Following the primary assessment, participants continue into an event-maintenance phase. The trial can last up to a total of 3 years and will enroll a total of approximately 2,500 participants.
The primary endpoint in the Phase 3 ZUPREME trials is percentage change in body weight from baseline to week 64. Secondary endpoints include, but are not limited to, change in waist circumference, HbA1c, cardiometabolic risk factors, physical functioning, and change in eating behaviors.
1 Like
Mye rart som kan oppstå innenfor medisin 
:
About ART27.13… … evaluating ART27.13 as a supportive care therapy for cancer patients suffering from anorexia and weight loss
1 Like
Vilt!
4 Likes
Lilly’s Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks
These additional analyses build on findings of the ACHIEVE-3 head-to-head study, where Foundayo 9 mg and 17.2 mg delivered greater A1C and weight reductions than oral semaglutide 14 mg
INDIANAPOLIS, Sept. 29, 2026 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes. The findings are based on an indirect treatment comparison of Foundayo 17.2 mg against oral semaglutide 25 mg, drawing on data from ACHIEVE-3 and PIONEER PLUS.1,2,3,4 Presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, these results add to a growing body of evidence supporting Foundayo’s efficacy.
“For someone managing type 2 diabetes, the choice between treatments is a decision that impacts their life every day,” said Deborah Horn, D.O., director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston. “Having data to help us compare available medications provides clinicians the opportunity to make informed treatment choices that fit each patient’s needs.”
In an indirect treatment comparison using data from ACHIEVE-3 and PIONEER PLUS, Foundayo 17.2 mg showed significantly greater weight loss and A1C reduction compared to oral semaglutide 25 mg at 52 weeks.5 On average, participants taking Foundayo 17.2 mg lost 1.5% more of their body weight compared to oral semaglutide 25 mg (95% CI -2.7%, -0.2%). Additionally, Foundayo lowered A1C by 0.3% more than oral semaglutide 25 mg (95% CI -0.6%, -0.1%). This analysis was covariate-adjusted for gender, age, baseline A1C and baseline weight. Analyses using different statistical methods produced consistent results, with Foundayo 17.2 mg showing 1.5% to 2.4% greater weight loss and 0.3% to 0.6% greater A1C reduction compared to oral semaglutide 25 mg.
“Head-to-head trials ultimately provide the best comparison of two medicines, but when we don’t yet have those data, then other approaches can provide informative data points,” said Rachel Batterham, OBE, MBBS, Ph.D., FRCP, senior vice president of medical innovation and external engagement, Lilly Cardiometabolic Health. “Results from this indirect treatment comparison suggest that Foundayo may deliver A1C and weight lowering that is similar to the 25 mg dose of oral semaglutide. These results, paired with simple administration free of fasting or water restrictions, are what make Foundayo a potentially foundational therapy for adults managing type 2 diabetes around the world.”
Lilly’s Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
In this new analysis, Zepbound 15 mg showed 4.5% greater weight loss than Wegovy HD in adults with obesity
Participants receiving Zepbound 15 mg had more than three times the odds of achieving at least 20% body-weight reduction compared with Wegovy HD
INDIANAPOLIS, Sept. 29, 2026 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY), the maker of Foundayo (orforglipron), today announced results from a new analysis showing that Zepbound (tirzepatide) 10 mg and 15 mg, a dual GIP and GLP-1 receptor agonist, delivered greater weight loss than Wegovy HD (semaglutide injection 7.2 mg) in adults with obesity. The findings come from an indirect treatment comparison of Zepbound and Wegovy HD, drawing on data from the SURMOUNT-1 and STEP UP trials.1,2,3 These results, presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, add to the growing body of evidence comparing Zepbound and Wegovy, including SURMOUNT-5, a randomized controlled Phase 3b trial in which Zepbound 10 mg and 15 mg demonstrated superior weight loss compared with Wegovy 1.7 mg and 2.4 mg.
“For people living with obesity, the choice of treatment matters, and clinicians increasingly want evidence on how the available options compare,” said John Wilding, DM, professor of medicine at the University of Liverpool. “Tirzepatide 10 mg and 15 mg and semaglutide 1.7 mg and 2.4 mg were compared directly in SURMOUNT-5, where tirzepatide helped people with obesity lose more weight. In the absence of a head-to-head trial comparing tirzepatide 15 mg against semaglutide 7.2 mg, this indirect comparison offers useful evidence for physicians as they make treatment decisions.”
In the indirect treatment comparison, which was covariate-adjusted for gender, age, baseline weight and baseline A1C, Zepbound 10 mg and 15 mg were associated with greater reductions in body weight than Wegovy HD at 72 weeks using the treatment-regimen estimand.4,5 Participants taking Zepbound 15 mg lost 4.5% more of their body weight (95.0% CrI: -6.3, -2.8) on average, and those taking 10 mg lost 3.2% more of their body weight (95.0% CrI: -5.0, -1.4). Using the efficacy estimand, Zepbound 15 mg and 10 mg were associated with 1.8% (95.0% CrI: -3.8, 0.1) and 0.7% (95.0% CrI: -2.6, 1.3) greater mean weight reduction than Wegovy HD, respectively, though these differences did not reach statistical significance.6
“People with obesity have more treatment options than ever before, and their healthcare providers deserve as much information as possible to help guide their decisions,” said Thomas Seck, M.D., senior vice president of product development, Lilly Cardiometabolic Health. “In a head-to-head Phase 3 clinical trial, Zepbound 10 mg and 15 mg delivered greater weight loss than Wegovy 1.7 mg and 2.4 mg, and a new indirect treatment comparison suggests the same doses of Zepbound may outperform Wegovy HD, as well. Together, these results offer physicians more information as they choose a treatment path.”
In addition to achieving greater weight loss, participants taking Zepbound 15 mg were four times more likely to achieve 20% or greater body weight reduction compared with Wegovy HD using the efficacy estimand (odds ratio 4.15; 95.0% CrI: 1.02, 15.64), and more than three times more likely using the treatment-regimen estimand (odds ratio 3.54; 95.0% CrI: 1.05, 11.05). While not statistically significant, participants taking Zepbound 10 mg had more than two times the odds of achieving at least 20% body-weight reduction compared with Wegovy HD using the efficacy (odds ratio 2.8; 95.0% CrI: 0.7, 10.8) and treatment-regimen estimands (odds ratio 2.46; 95.0% CrI: 0.7, 7.8).
Zepbound 10 mg and 15 mg showed comparable rates of treatment discontinuation due to adverse events versus Wegovy HD across both estimands.
Lilly’s triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
Lilly’s oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
In post-hoc analyses of ATTAIN-1, Foundayo 17.2 mg was associated with a predicted 57% and 18% reduction in risk of type 2 diabetes and cardiovascular disease vs. placebo
Combined with recent research on the savings tied to weight loss, these findings suggest Foundayo could help reduce long-term spending for patients and healthcare systems
INDIANAPOLIS, Oct. 1, 2026 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo was associated with significant reductions in predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight with a weight-related medical problem. Obesity is strongly associated with an increased risk of developing both cardiovascular disease and type 2 diabetes.1 Through its proven benefit in weight loss and its ability to improve certain cardiovascular risk factors like blood sugar, blood pressure and cholesterol, Foundayo may be a meaningful treatment option for the more than 100 million U.S. adults living with obesity.2 The findings of these analyses were published in Diabetes, Obesity and Metabolism .
“For many people living with obesity or overweight, the concern isn’t just what the scale says today, it’s whether their future could include type 2 diabetes or heart disease,” said Thomas Seck, M.D., senior vice president of product development, Lilly Cardiometabolic Health. “These additional analyses of ATTAIN-1 show that Foundayo was associated with a lower predicted long-term risk of both conditions, in addition to meaningful weight loss. We’ve also seen evidence that treating obesity and reducing the risk of its downstream consequences, like cardiovascular disease and type 2 diabetes, can meaningfully lower healthcare costs.3,4,5 That gives us real optimism about what long-term Foundayo use could mean, both for patients and for the broader healthcare system.”
In these analyses, modeling showed that Foundayo was associated with clinically meaningful improvements in predicted 10-year risk of type 2 diabetes and cardiovascular disease across all three doses.6 At 72 weeks, participants taking Foundayo 5.5 mg, 9 mg and 17.2 mg showed an estimated 45.0%, 50.0% and 57.0% reduction, respectively, in predicted type 2 diabetes risk versus placebo.7,8 Participants taking Foundayo 17.2 mg also showed an estimated 18.0% reduction in predicted cardiovascular disease risk versus placebo.
1 Like
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
2026-09-30 00:03:00
Press release – No. 18 / 2026
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
- Treatment with petrelintide was associated with clinically meaningful, double-digit weight loss, with a gastrointestinal tolerability profile comparable to placebo
- Treatment was associated with significant improvements in cardiometabolic disease risk factors, including reductions in pulse rate, high-sensitivity C-reactive protein and waist circumference
- Additional results from the ZUPREME-1 study will be presented in an oral presentation at EASD 2026 on September 30 at 3:30pm CEST
- A global Phase 3 ZUPREME registrational program with petrelintide monotherapy for chronic weight management has been initiated
Copenhagen, Denmark, September 30, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces that results from its Phase 2 ZUPREME-1 trial evaluating investigational petrelintide have been published in The Lancet Diabetes & Endocrinology . The data will be presented at the 62nd Annual meeting of the European Association for the Study of Diabetes (EASD) 2026 on September 30, 2026, at 3:30pm CEST.
In the randomized, double-blind, placebo-controlled, dose-finding ZUPREME-1 trial, 485 adults (53% female; mean age 47 years; BMI 36.7 kg/m²; body weight 107.1 kg) were randomly assigned (5:1) to once-weekly subcutaneous injections of petrelintide at 1.0 mg, 2.5 mg, 5.0 mg, 7.0 mg or 9.0 mg, or to placebo, for 42 weeks including dose escalation.
Data reinforce the potential of petrelintide to enhance treatment persistence and address current challenges of treatment durability, tolerability and acceptability.
Key Findings
- Petrelintide led to mean reductions in body weight from baseline to week 42 of up to 10.7% vs 1.7% for placebo (efficacy estimand)
- Using the treatment policy estimand, petrelintide led to mean reductions in body weight from baseline to week 42 of up to 10.2% vs 1.4% for placebo
- Gastrointestinal adverse events were generally mild and occurring at rates similar to placebo; at petrelintide’s maximally effective dose, there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events.
- Petrelintide was associated with meaningful improvements in key cardiometabolic risk factors, with reductions in waist circumference of up to 10.8 cm (versus 4.3 cm with placebo), up to 41% reductions in high-sensitivity C-reactive protein (versus 6% with placebo), and reductions of triglycerides of up to 21% (vs 9% with placebo), along with a mean reduction in pulse rate of up to 2.9 beats per minute (bpm) versus a mean increase of 0.3 bpm with placebo.
Petrelintide is being evaluated for chronic weight management in three global Phase 3 registrational trials. For more information about the Phase 3 program, refer to Zealand Pharma Press Release no. 17 / 2026.
2 Likes